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Human intestinal microbiota plays an important role in the maintenance of host health by providing
energy, nutrients, and immunological protection. Intestinal dysfunction is a frequent complaint in
myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) patients, and previous reports suggest
that dysbiosis, i.e. the overgrowth of abnormal populations of bacteria in the gut, is linked to the
pathogenesis of the disease.
We used high-throughput 16S rRNA gene sequencing to investigate the presence of speciﬁc alterations
in the gut microbiota of ME/CFS patients from Belgium and Norway. 43 ME/CFS patients and 36 healthy
controls were included in the study. Bacterial DNA was extracted from stool samples, PCR ampliﬁcation
was performed on 16S rRNA gene regions, and PCR amplicons were sequenced using Roche FLX 454
sequencer.
The composition of the gut microbiota was found to differ between Belgian controls and Norwegian
controls: Norwegians showed higher percentages of speciﬁc Firmicutes populations (Roseburia, Holde-
mania) and lower proportions of most Bacteroidetes genera. A highly signiﬁcant separation could be
achieved between Norwegian controls and Norwegian patients: patients presented increased pro-
portions of Lactonifactor and Alistipes, as well as a decrease in several Firmicutes populations. In Belgian
subjects the patient/control separation was less pronounced, however some abnormalities observed in
Norwegian patients were also found in Belgian patients.
These results show that intestinal microbiota is altered in ME/CFS. High-throughput sequencing is a
useful tool to diagnose dysbiosis in patients and could help designing treatments based on gut micro-
biota modulation (antibiotics, pre and probiotics supplementation).
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license. 1. Introduction
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
is a debilitating disease with a worldwide prevalence of 0.4e1%.
According to the deﬁnition of Fukuda et al. [1], ME/CFS patients
present a clinically evaluated, unexplained fatigue accompanied by
at least four of the following symptoms: memory impairment, sore: þ32 2 481 53 11.
t).
r Ltd. Open access under CC BY-NC-throat, tender lymph nodes, muscle or joint pain, headaches,
unrefreshing sleep, post-exertional malaise. A number of condi-
tions such as malignancies and certain viral infections exclude a
diagnosis of ME/CFS. The pathogenesis of the disease is still poorly
understood, but probably involves multiple factors such as in-
fections, stress, and neuroendocrine impairments [2].
A number of observations suggest that gastro-intestinal dys-
functions also contribute to the onset and/or maintenance of the
disease [3]. There is a striking lifetime rate (92%) of irritable bowel
syndrome (IBS) among ME/CFS patients [4]; co-occurrence of ME/
CFS and IBS is associated with increased plasma levels of pro-
inﬂammatory cytokines such as IL-6, IL-8, IL-1b and TNFa [5], a
systemic inﬂammatory situation which may in part be due to the
translocation of commensal bacteria resulting from an increasedSA license. 
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integritymay therefore contribute to the pathogenesis of the disease.
A growing body of literature is linking intestinal and immune
dysfunctions with alterations in the composition of the gut
microbiota. Intestinal bacteria play major roles in breakdown and
synthesis of nutrients, prevention of infection by pathogenic or-
ganisms, regulation of mucosal and systemic immunity, and even
CNS function (the “gut-brain” axis), inﬂuencing emotional behav-
iors such as anxiety and depression. Overgrowth or deﬁciencies of
speciﬁc bacterial populations have been associated with various
disorders, including IBS, Crohn’s disease, allergies, autoimmune
diseases, diabetes and cancer [7e11].
Alterations in gut microbiota composition have already been
reported for ME/CFS. In 2003 Logan et al. [12] hypothesized that
low levels of biﬁdobacteria and small intestinal bacterial over-
growth (SIBO) could result in immune dysfunctions in ME/CFS
patients. Using culture-based assays, Sheedy et al. [13] observed
signiﬁcantly increased proportions of D-lactic acid-producing
Enterococcus and Streptococcus spp. in faecal samples of ME/CFS
patients. Excess D-lactic acid production could contribute to mito-
chondrial dysfunction, but also to neurocognitive impairments in
patients, since D-lactic acidosis is known to affect CNS function. The
link between intestinal microbiota and cognitive problems was
further supported by a study reporting a positive effect of probiotic
supplementation (Lactobacillus casei) on emotional and anxiety
symptoms in ME/CFS patients [14]. In another study, administra-
tion of probiotic strains (Lactobacillus paracasei, Lactobacillus aci-
dophilus, Biﬁdobacterium lactis) also resulted in a signiﬁcant
improvement of neurocognitive functions, but not of fatigue and
physical activity scores [15]. These results warranted further
studies on gut microbiota composition in ME/CFS.
Recently, new technologies based on metagenomics/high-
throughput sequencing have been developed and successfully
applied to the analysis of the complex bacterial ecosystem of the
gut. These new analytical approaches usually involve DNA extrac-
tion (from stool samples or biopsies) and ampliﬁcation of 16S ri-
bosomal RNA gene followed by high-throughput sequencing. By
sequence analysis, several thousands of bacteria can be identiﬁed in
each sample. Whereas previous culture-based assays could only
address cultivable organisms (which only represent a small pro-
portion of the hundreds of species inhabiting the gut), sequencing-
based molecular technologies can give a comprehensive overview
of the gut microbiota, including the four major phyla Actino-
bacteria, Bacteroidetes, Firmicutes and Proteobacteria, and have
already revealed associations betweenmicrobiota composition and
disorders like obesity, IBS, allergies, and autism [16e19].
In this study, we used a high-throughput sequencing approach
to investigate the microbiota composition of stool samples from
Belgian and Norwegian ME/CFS patients. Signiﬁcant alterations in
microbiota composition were observed in patients compared to
matched healthy controls, suggesting an involvement of intestinal
dysbiosis in the pathogenesis of the disease.
2. Patient selection, methods
2.1. Patient selection
The following subjects were recruited for the study: Belgian
healthy controls (n ¼ 19, 15 women and 4 men, mean age 41 12.6,
median age 41), Belgianpatients (n¼ 18,15women and3men,mean
age 38.513,median age 37), Norwegian healthy controls (n¼ 17,14
women and 3 men, mean age 45  19, median age 49), Norwegian
patients (n¼ 25, 22 women and 3men, mean age 4112.5, median
age 42). All subjects were Caucasians. Patients were diagnosed for
CFS according to the clinical criteria of Fukuda et al. [1]. 14 out of the18 Belgian patients, and 20 out of the 25 Norwegian patients, pre-
sented moderate to severe intestinal symptoms (pain, diarrhea,
bloating). Illness duration was 7  4 years for the Belgian patients,
12  9 years for the Norwegian patients. The subjects had not been
taking antibiotics or probiotics for four weeks prior to sample
collection; they gave written informed consent to the study.
2.2. Sample collection, DNA extraction
Samples of homogenized stool were collected and directlymixed
with 2 ml of Aquastool solution (Multi Target Pharmaceuticals, Salt
Lake City, USA). Aquastool stabilizes the sample and prevents any
modiﬁcation of microbiota composition, even in samples stored for
up to four days at room temperature (information provided by the
manufacturer). For long term storage samples were kept at 20 C.
For DNA extraction, the stool sample was centrifuged and washed
twice with PBS. After centrifugation, the supernatant was discarded
and the pellet resuspended in 2 ml of TE. One milliliter of the sus-
pensionwas mixed with 5 mg of Lysozyme (Sigma) and glass beads
(Sigma) and incubated at 37 C for 1 h and 30min in a thermomixer
(1400 rpm). After adding 32 ml of proteinase K (20mg perml, Roche)
and 400 ml of SDS (10%), the samples were incubated at 55 C for 1 h.
Samples were further extracted using the DNeasy Blood and Tissue
kit (Qiagen) following manufacturer instructions.
2.3. PCR ampliﬁcation, high-throughput sequencing
16S rRNA genes were ampliﬁed using the primers AGGATTA-
GATACCCTGGTA and CRRCACGAGCTGACGAC targeting the V5 and
V6 hypervariable 16S rRNA regions [20]. For each sample, a PCRmix
of 100 ml was prepared containing 1 PCR buffer, 2 U of KAPA HiFi
Hotstart polymerase blend and dNTPs (Kapabiosystems), 300 nM
primers (Eurogentec, Liege, Belgium), and 60 ng gDNA. Thermal
cycling consisted of initial denaturation at 95 C for 5 min, followed
by 25 cycles of denaturation at 98 C for 20 s, annealing at 56 C for
40 s, and extension at 72 C for 20 s, with a ﬁnal extension of 5 min
at 72 C. Amplicons were visualized on 1% agarose gel using Gel-
Green Nucleic Acid gel stain in 1 TAE (Biotium) and were cleaned
using the Wizard SV Gel and PCR Clean-up System (Promega) ac-
cording to the manufacturer’s instructions.
Amplicon DNA concentrations were determined using the
Quant-iT PicoGreen dsDNA reagent and kit (Life Tech, Carlsbad,
USA) following the manufacturer’s instructions. After quantiﬁca-
tion, the DNAwas pooled and puriﬁed using Agencourt Ampure XP
Puriﬁcation systems according to the manufacturer’s instructions
(Agencourt Biosciences Corporation, Beckman Coulter, USA).
Pyrosequencing was carried out following the manufacturer in-
structions on a 454 Life Sciences Genome Sequencer FLX instru-
ment (Roche) using titanium chemistry.
The sequences were assigned to samples according to sample-
speciﬁc barcodes. Sequences were then checked for the following
criteria: (i) almost perfect match with barcodes and primers; (ii)
length of at least 240 nucleotides (barcodes and primers excluded);
(iii) no more than two undetermined bases (denoted by N). By
“almost perfect match”, we mean that one mismatch/deletion/
insertion is allowed in the barcode, idem for the primer. Each
sequence originating from pyrosequencing and passing QC was
assigned to a family by the RDP classiﬁer (v 2.1) with CE > 80%. The
Shannon and Chao richness estimates were done through the
Mothur package [21].
2.4. Statistical analysis
Data were analyzed using ManneWhitney test and linear
discriminant analysis. The ManneWhitney hypothesis test
Group Centroid
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discriminant analysis (LDA) was applied to map the discriminatory
performance of sets of bacteria with respect to the population
samples. The ﬁrst and second discriminant function scores were
used for display [22e24]. The signiﬁcance of LDA was tested using
the associated MANOVA Wilk’s Lambda test. All results were
deemed signiﬁcant if the p-value was below 0.05, the level of sig-
niﬁcance adopted.
The data analysis was performed using SPSS (Statistical Package
for the Social Sciences, IBM, Armonk, USA) version 14.0.Fig. 1. Discriminant function analysis separates the sample into distinct clusters. 1:
Belgian patients; 2: Belgian controls; 3: Norwegians patients; 4: Norwegian controls.3. Results
3.1. Number of reads per sample, classiﬁcation of assigned
sequencing by phylum, family and genus
On average, 6000e7000 reads were obtained per sample. For all
samples, at least 98% of reads could be assigned to a speciﬁc phylum
(usually more than 99% assignation). Represented phyla were Fir-
micutes, Bacteroidetes, Proteobacteria and Actinobacteria; in some
samples bacteria belonging to the phyla Euryarchaeota, Fusobac-
teria, Verrucomicrobia or Lentisphaerae could be detected but in
very small proportions (not more than 0.02% of total reads).
As expected, and due to the stringent criteria used for sequence
analysis and classiﬁcation, the number of reads that could be
assigned with certainty to a speciﬁc family or a speciﬁc genus was
lower (60e80% assignation at the family level, 30e60% assignation
at the genus level).
129 Different bacterial genera could be identiﬁed from the 79
samples included in the study. A majority of these however were
present only in a few samples (sometimes just one or two subjects,
in a very small proportion).
Genera represented in almost all subjects (there were always
exceptions, in both controls and patients) were Anaerostipes, Bac-
teroides, Blautia, Biﬁdobacterium, Butyricicoccus, Coprococcus, Dorea,
Faecalibacterium, Oscillibacter, Roseburia, Ruminococcus, Sub-
doligranulum. Among those, the usually dominant genera were
Biﬁdobacterium (very variable, from 0 to more than 50%), Blautia
(15e60%), Coprococcus (2e3% up to 30%), Dorea (usually 5e15%),
Faecalibacterium (usually 5e20%), Roseburia (up to 45% in some
samples).
Many genera were characterized by a strong variability in term
of representativity, being absent in some samples but forming a
signiﬁcant percentage of the total bacterial population in others.
Lactonifactor was usually low or absent, but could reach more than
7% in some samples. Clostridiumwas anywhere between 0 and 15%.
Usually below 5%, Streptococcus reached 15%, 44% and 60% in three
subjects. Other genera showing high variability were Dialister,
Colinsella, Prevotella, Asaccharobacter, Alistipes.3.2. Geographical origin of the sample and microbiota composition
There were strong variations of diversity index between in-
dividuals: non-parametric Shannon index (OTU cutoff 0.10) varied
from 2.6 to 3.54 in Belgian controls, from 2.2 to 3.7 in Norwegian
controls. However, average diversity index did not differ signiﬁ-
cantly between the four populations.
Discriminant function analysis was performed using percent-
ages of the different bacterial genera as variables. The four groups
of samples clustered separately, and the separationwas statistically
signiﬁcant (p ¼ 0.022). ME/CFS patients therefore appear to have a
different gut microbiota composition than healthy controls; dif-
ferences could also be seen between the healthy controls of the two
different geographical origins (Fig. 1).Interestingly Belgian and Norwegian patients diverged from
their corresponding controls in two different ways: alterations seen
in Belgian patients may therefore at least partially differ from the
alterations seen in Norwegian patients.
The ManneWhitney test was used to compare Belgian controls
with Norwegian controls. Norwegian controls presented a signiﬁ-
cantly lower percentage of Bacteroidetes bacteria (p ¼ 0.026) and a
3-fold increase of the Firmicutes/Bacteroidetes ratio.
At the genus level, Norwegians showed higher percentages of
speciﬁc Firmicute populations compared to Belgians: an average
1.7-fold increase of Roseburia (p ¼ 0.048), and a 3-fold increase of
Holdemania (p ¼ 0.008). They showed lower proportions of several
Bacteroidetes genera: three times less Bacteroides (p ¼ 0.015), ﬁve
times less Alistipes (p¼ 0.009), four times less Prevotella (p¼ 0.002)
(Table 1).
3.3. Alterations of intestinal microbiota in Norwegian patients
Discriminant function analysis achieved a highly signiﬁcant
separation (p< 0.001) between Norwegian controls and Norwegian
patients (Fig. 2). Variations in sub-populations of the Firmicutes
phylum (namely relative proportions of the genera Moryella,
Ethanoligenens, Ruminococcus, Eubacterium, Holdemania and Turi-
cibacter) were main contributing factors of this separation. In pa-
tients, populations of Ethanoligenens and Moryella are increased,
populations of Ruminococcus, Eubacterium, Holdemania and Turici-
bacter are decreased.
Between Norwegian controls and Norwegian patients, the most
signiﬁcant differences obtained by the ManneWhitney test were
for the Firmicutes genera Holdemania (50-fold decrease,
p ¼ 0.0001), Lactonifactor (20-fold increase, p ¼ 0.003), Syntro-
phococcus (2.5-fold decrease, p ¼ 0.015), but also for the Bacter-
oidetes Alistipes (3.8-fold increase, p ¼ 0.013) (Table 2).
3.4. Alterations of intestinal microbiota in Belgian patients
In Belgian subjects the patient/control distinction was less
pronounced (Fig. 3). The separation obtained by discriminant
function analysis was not signiﬁcant (although borderline,
p ¼ 0.072). Interestingly however, some of the variables which
Fig. 2. Discriminant function analysis allows excellent separation of the two pop-
ulations (3: Norwegian patients, 4: Norwegians controls), with no overlap.
Table 2
Variation of speciﬁc bacterial genera in Norwegian patients vs. Norwegian controls.
Levels of signiﬁcance: *p < 0.05, **p < 0.01.
Table 1
Variation of speciﬁc bacterial genera in Norwegian controls vs. Belgian controls.
Levels of signiﬁcance: *p < 0.05, **p < 0.01.
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which could also discriminate Norwegian patients from Norwegian
controls: proportions of Ethanoligenens, Ruminococcus, Eubacterium
were again main contributors in the discriminant function
(together with Blautia, Lactobacillus and Megasphera).
Using theManneWhitney test, only two variables were found to
differ signiﬁcantly between Belgian controls and Belgian patients:
the percentage of Asaccharobacter, a member of the ActinobacteriaFig. 3. Discriminant function analysis separates the two populations (1: Belgian pa-
tients, 2: Belgians controls), but the separation is less signiﬁcant than for the Nor-
wegian subjects.
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percentage of Lactonifactor which was again strongly increased in
patients (45-fold increase, p ¼ 0.006) (Table 3).
4. Discussion
Bacteria living in the intestine can exert a critical inﬂuence on
host health by synthesizing nutrients and vitamins, producing
beneﬁcial or toxic metabolites, inhibiting microbial and viral
pathogens, detoxifying food, and also by contributing to the
development of an optimally functioning immune system. 70% of
all immune cells are located in the gastro-intestinal tract, and their
interactions with bacterial antigens at the mucosal surface
contribute to the regulation of major immune mechanisms such as
tolerance, allergy and inﬂammation [8].
Acquisition of the intestinal microbiota occursmostly during the
ﬁrst twoethree years of life and is inﬂuenced by many factors:
environmental factors such as vaginal vs. Cesarean delivery, breast
vs. bottle feeding, lifestyle, use of antibiotics, but also host factors
such as immune system function and genetic background [8,25].
Host factors are probably largely responsible for the resilience of
the gut microbiota composition which, once established in the
young child, seems to remain relatively stable throughout life. In
the long term however, modiﬁcations of dietary habits can affect
the composition of the gut microbiota; the so-called “Western
diet”, high in sugar and fat, seems to favor the growth of Firmicutes
including Clostridium, Eubacterium, Enterococcus spp., and decrease
several Bacteroides spp. Consumption of reﬁned sugars mediates
the overgrowth of opportunistic Clostridium difﬁcile and Clostridium
perfringens, whereas complex carbohydrates favor beneﬁcial Biﬁ-
dobacteria spp. [26].
These modiﬁcations are suspected to affect the host inﬂamma-
tory and metabolic responses, and disruption of intestinal micro-
biota equilibrium has been associated with several diseases. In
most cases however it is not clear how speciﬁc bacterial pop-
ulations contribute to pathogenesis. Deﬁning a “normal” intestinal
microbiota is probably not possible: adult gut microbiota compo-
sition varies dramatically from one individual to another, with
differences in the ratios of dominant phyla, as well as in the pres-
ence and proportions of multiple genera and species. Depending on
host genetics and dietary factors, a speciﬁc microbiota may be
symbiotic or commensal in some individuals, but have detrimental
activities, and predispose to certain diseases, in other people.
The large majority of all sequences identiﬁed in our subjects
(controls and patients) belonged to one of the four phylaTable 3
Variation of speciﬁc bacterial genera in Belgian patients vs. Belgian controls. Levels
of signiﬁcance: *p < 0.05, **p < 0.01.Actinobacteria, Bacteroidetes, Firmicutes or Proteobacteria, which
is in agreement with previous reports from human gut microbiota
studies [27]. However the relative proportions of these major phyla
differed from one individual to another: geographical origin of the
sample had an inﬂuence on the Firmicutes/Bacteroidetes ratio
which was signiﬁcantly higher in Norwegian samples than in
Belgian samples.
This difference may be due to genetic and/or dietary factors. A
recent study, using the same methodology as ours, found that
Actinobacteria and Bacteroidetes were more abundant in African
children’s microbiota, whereas in Italian children, Firmicutes was
the dominant phyla [28]. Bacteroidetes bacteria like Xylanibacter
and Prevotella are able to ferment plant polysaccharides (xylan,
cellulose) which are present in the rural African diet but much less
in the food consumed in industrialized countries; it was hypothe-
sized that the dominance of Bacteroidetes in African children was
an adaptation to the available diet, allowing individuals to maxi-
mize energy intake from ﬁbre-rich food.
Although there may be differences between Belgian and Nor-
wegian diets, the differences observed in our study may also result
from the inﬂuence of genetic background. Any gene involved in
mucosal immunity regulation, production of mucin or anti-
bacterial defensins by gut epithelial cells, could potentially inﬂu-
ence the composition of the microbiota, and further studies should
investigate how polymorphisms in such genes can affect the ﬁnal
composition of the gut ecosystem. A number of genes involved in
mucosal immunity such as IRAK3, IL22, IFNG, ATG16L, TLRs and
CARD15/NOD2 have already been related to alterations of gut
microbiota composition [25,29].
Our study has revealed alterations of gut microbiota composi-
tion in ME/CFS patients, which were more signiﬁcant in the Nor-
wegian subjects. Norwegian patients differ from their matched
controls by showing decreased percentages of several Firmicutes
sub-populations (Roseburia, Syntrophococcus, Holdemania, Dia-
lister), a strong 20-fold increase of Lactonifactor, and a 3.8-fold in-
crease of the Bacteroidetes genus Alistipes.
Syntrophococcus and Holdemania are poorly characterized
genera, it is difﬁcult to discuss how their decrease in patients can be
associated with ME/CFS pathogenesis. Roseburia is a major
butyrate-producing genus; as such these bacteria contribute to
colon epithelium health, production of energy, and protection
against gut inﬂammation [30]. Dialister is best known clinically for
its association with periodontal disease [31], however its presence
in the gut may not be detrimental; actually a decrease of Dialister
invisus in fecal samples from patients with Crohn’s disease has
already been reported [32]. Increase of Alistipes can also be related
to gut inﬂammation: higher levels of Alistipes taxa are associated
with greater frequency of abdominal pain in irritable bowel syn-
drome (IBS) patients [33], and actually the bacteria was ﬁrst
described as a Bacteroides-related, bile-resistant rod often isolated
from appendicitis tissue [34].
Alterations of gut microbiota observed in Norwegian patients
are therefore consistent with an increased intestinal inﬂammation,
which is suspected to occur in ME/CFS patients [3e6].
It is of course notable that the Firmicutes/Bacteroidetes ratio did
not decrease to such an extent in the Belgian patients. This may
reﬂect a different disease pathogenesis, but may also simply result
from the differences already existing in the control populations.
Firmicute populations are already low in the Belgian controls;
whether this predisposes Belgians to gut inﬂammation, or simply
represents a healthy adaptation to different genetic background
and diet, is unclear.
Norwegian patients are slightly older than Belgian patients
(mean age 41 vs. 38.5) and tend to have been sick for a longer
period of time (12  9 vs. 7  4 years). This longer illness duration
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Norwegian patients, however statistical analysis did not reveal any
signiﬁcant correlation between microbiota composition and time
since disease onset.
Recently Arumugam et al. [35] reported the results of a meta-
genomic study involving 39 individuals from different geographical
origins. They found that samples could be grouped into three
distinct clusters (called enterotypes), driven by species composi-
tion. The dominant species in these three clusters were Rumino-
coccus, Prevotella and Bacteroides, respectively.
Although Arumugam et al. did not observe any relation between
the geographical origin of the samples and their grouping into a
speciﬁc cluster, it is notable that in our study, Bacteroides and Pre-
votellawere two of the species which differentiated the Norwegian
controls from the Belgian controls. None of the three species,
however, was involved in the separation between controls and
patients, so there is no evidence that disease could be associated
with a shift from one speciﬁc enterotype to another.
A remarkable similarity between Norwegian and Belgian pa-
tients was the strong, speciﬁc increase of Lactonifactor (20-fold in
Norwegian patients, 45-fold in Belgian patients). Lactonifactor is a
Firmicute from the Clostridiaceae family. Although this genus is not
very well characterized, it is known to be involved in the conver-
sion of lignan phytoestrogens into bioactive enterodiol (ED) and
enterolactone (EL) [36,37]. In Belgian patients, the increase of Lac-
tonifactor was paralleled by a decrease of the Actinobacteria Asac-
charobacter. The association of these two alterations may be
signiﬁcant, since Asaccharobacter is also involved in themetabolism
of phytoestrogens, being able to convert isoﬂavones like daidzein
into equol [38,39]. One could hypothesize that intestinal dysbiosis
contributes to ME/CFS through altered production of estrogen re-
ceptor (ER) agonists/antagonists, which could interact with
estrogen-dependent pathways. Obviously the predominance of
women among patients, the fact that disease symptoms change
upon e.g. puberty, pregnancy and menopause, has long suggested
an involvement of hormones in ME/CFS and actually ERb, the
preferred receptor of equol, is down-regulated in patients [40,41].
Disruption of estrogen signaling is therefore an interesting hy-
pothesis, quite consistent with some dysfunctions observed in ME/
CFS. It could be related, for instance, with immune dysregulation
since isoﬂavones and more speciﬁcally equol induce expression of
antioxidant enzymes, and exert an anti-inﬂammatory action by
inhibiting the production of IL-6, TNF-a and inducible nitric oxide
synthase in LPS-stimulated macrophages [42,43].
Another potentially relevant aspect of phytoestrogens and their
metabolites is their capacity to regulate vitamin D receptor (VDR)
activity, and vitamin D synthesis. Similar to 17b-estradiol, phy-
toestrogens can induce expression of VDR in gut epithelial cells;
they also regulate several cytochrome P450 enzymes which are
integral part of vitamin D synthesis pathways [44]. The vitamin D
system is critical for maintenance of gut mucosal immunity, and
several reports have shown a link between vitamin D, VDR, and
inﬂammatory intestinal diseases [45,46]. VDR-mediated signaling
can antagonize TNF-a, IL-17, IL-6, IL-1 inmacrophages and dendritic
cells and prevent development of inﬂammatory bowel disease.
Vitamin D has also been shown to modulate T-cell antigen receptor
and induce FoxP3, which is critical for prevention of mucosal
inﬂammation [47,48].
A number of observations suggest an alteration of VDR function
in ME/CFS [49]. The potential interaction of gut bacteria metabo-
lites with the regulation mechanisms of VDR is therefore an
interesting mechanism which could explain this important aspect
of the disease.
Our study has revealed signiﬁcant alterations of intestinal
microbiota in ME/CFS patients. Metagenomic high-throughputsequencing has only recently been applied to the analysis of gut
microbiota; as a result, most of the bacterial genera identiﬁed by
this technique are still poorly characterized, and a lot has still to be
learned about their inﬂuence on gut function and human health.
However, given the state of the knowledge, the various alterations
observed seem consistent with the hypothesis of an increased in-
testinal inﬂammation in ME/CFS; they also suggest a possible
mechanism where bacterial metabolites could contribute to the
disease by interfering with estrogen receptor and VDR pathways.
Further experiments are being designed to test these hypotheses;
for instance the combination of metagenomic microbiota analyses
with metabolomic approaches (broad range analysis of metabolites
of human and bacterial origin present in stool, urine or plasma
samples) could help establish some links between the presence of
speciﬁc bacterial populations, and the modiﬁcation of human
physiological mechanisms.
Like most gut microbiota studies published so far, the present
study has been analyzing bacterial populations in stool samples.
Some authors have suggested that stool bacteria are merely
representative of the luminal microbiota, which is not necessarily
identical to the bacterial populations living in close contact with
the gut mucosa [50]. Mucosa-associated populations, however,
differ from one place of the digestive tract to another. The stool
sample may therefore provide a more representative view of the
global microbiota than a single punch biopsy.
A question of major importance is of course the causal rela-
tionship between gut microbiota alterations and disease onset;
this point still has to be clariﬁed. Is altered gut microbiota a pre-
existing, causative or at least predisposing factor for the disease?
Or do microbiota alterations occur as a consequence of the dis-
ease, triggered by stress, immune dysfunctions or pathogen in-
fections in the intestine? For instance, we and others have
reported the presence of persistent viral infections (enterovirus,
parvovirus B19, herpesviruses) in the gastro-intestinal tract of
ME/CFS patients [51,52]. These viruses could reactivate as a
consequence of altered mucosal immunity caused by bacterial
dysbiosis (replication of herpesviruses is favored by inﬂamma-
tion); but since some of these viruses have potent immunosup-
pressive effects, the reverse mechanism where a viral infection
causes a change in mucosal immunity, which in turn leads to gut
microbiota alterations, is also possible. Longitudinal studies
examining the evolution of microbiota over a certain period of
time, through relapses and remission, or before and after treat-
ments, could already give a partial answer. Further studies will
have to clarify the complex relationships between bacterial
microbiota, viral infections, host immune system and genetic
background.5. Conclusions
High-throughput rRNA gene sequencing proved to be a useful
tool to diagnose dysbiosis in ME/CFS patients. Our results suggest
new pathogenesis mechanisms for ME/CFS, but also open new
possibilities regarding the design of treatments based on gut
microbiota modulation using antibiotics, pre and probiotics
supplementation.Acknowledgments
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